Natural remedies for scleroderma

Alternative Medicine Review

Volumn 11, Issue 3, 2006, Pages 188-195

  Gaby, Alan R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOATE POTASSIUM; 4 AMINOBENZOIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; BROMELAIN; CALCITRIOL; COPPER; ERGOCALCIFEROL; ESTRIOL; GAMMA LINOLENIC ACID; GLUCOCORTICOID; PENICILLAMINE; PENICILLIN G; PIASCLEDINE; PLACEBO; PRIMROSE OIL; PROSTAGLANDIN E1; S ADENOSYLMETHIONINE; VITAMIN D; ZINC;

ABSENCE OF SIDE EFFECTS; ALTERNATIVE MEDICINE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE; DIET; DIET THERAPY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; ENVIRONMENTAL FACTOR; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOGLYCEMIA; OXIDATIVE STRESS; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN; SYNDROME CREST; UNSPECIFIED SIDE EFFECT; URTICARIA;

HUMANS; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC;

EID: 33749568950     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Gough A, Sheeran T, Bacon P, Emery P. Dietary advice in systemic sclerosis: the dangers of a high fibre diet. Ann Rheum Dis 1998;57:641-642.
2. Crinnion WJ. Results of a decade of naturopathic treatment for environmental illnesses: a review of clinical records. J Naturopathic Med 1997;7:21-27.
3. Zarafonetis CJ. Para-aminobenzoic acid therapy in scleroderma and lymphoblastoma cutis. J Lab Clin Med 1948;33:1462-1463.
4. Zarafonetis CJ. The treatment of scleroderma: results of potassium para-aminobenzoate therapy in 104 cases. In: Mills LC, Moyer JH, eds. Inflammation and Diseases of Connective Tissue. W.B. Saunders Co.; 1961:688-696.
5. Zarafonetis CJ, Dabich L, De vol EB, et al. Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. Respiration 1989;56:22-33.
6. Zarafonetis CJ, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol 1988;41:193-205.
7. Grace WJ, Kennedy RJ, Formato A. Therapy of scleroderma and dermatomyositis. N Y State J Med 1963;63:140-144.
8. Bushnell WJ, Galens GJ, Bartholomew LE, et al. The treatment of progressive systemic sclerosis: a comparison of para-aminobenzoate and placebo in a double blind study. Arthritis Rheum 1966;9:495-496.
9. Clegg DO, Reading JC, Mayes MD, et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 1994;21:105-110.
10. Stein CM, Tanner SB, Awad JA, et al. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-1150.
11. Ayres S Jr, Mihan R. Is vitamin E involved in the autoimmune mechanism? Cutis 1978;21:321-325.
12. Ayres S Jr, Mihan R. Vitamin E (tocopherol) - a reappraisal of its value in dermatoses of mesodermal tissues. Cutis 1971;7:35-45.
13. Ayres S Jr, Mihan R. Vitamin E and dermatology. Cutis 1975;16:1017-1021.
14. Kraus Z. Fibrosis of the lungs in scleroderma. Nutr Abs Rev 1950;20:452.
15. Ayres S Jr, Mihan R, Levan NE, et al. Raynaud's phenomenon, scleroderma and calcinosis cutis: response to vitamin E. Cutis 1973;11:54-62.
16. Ayres S Jr, Mihan R, Levan NE. Raynaud's phenomenon and possibly early scleroderma - response to vitamin E. Arch Dermatol 1971;104:570-571.
17. Maynard MT. Vitamin therapy in dermatology. With particular reference to vitamin D in the treatment of acne and of diseases due to altered usage of calcium. Arch Derm Syphilol 1940;41:842-857.
18. Humbert PG, Dupond JL, Rochefort A, et al. Localized scleroderma - response to 1,25-dihydroxy vitamin D3. Clin Exp Dermatol 1990;15:396-398.
19. Hulshof MM, Pavel S, Breedveld FC, et al. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994;130:1290-1293.
20. Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999;16:53-58.
21. Humbert P, Dupond JL, Agache P, et al. Treatment of scleroderma with oral 1,25-dihydroxy vitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 1993;73:449-451.
22. Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000;43:1017-1023.
23. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89:5387-5391.
24. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001;73:288-294.
25. Martin MF, Tooke JE. Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis. Br Med J (Clin Res Ed) 1982;285:1688-1690.
26. Strong AM, Campbell A, Thomson J. The effect of oral linoleic acid and gamma-linolenic acid (Efamol [G]). Br J Clin Pract 1985;39:444-445.
27. Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost 1985;54:490-494.
28. Stainforth JM, Layton AM, Goodfield MJ. Clinical aspects of the use of gamma linolenic acid in systemic sclerosis. Acta Derm Venereol 1996;76:144-146.
29. Lieb J. Linoleic acid in the treatment of lithium toxicity and familial tremor. Prostaglandins Med 1980;4:275-279.
30. Katayama H, Ohsawa K, Yaoita H. Improvement of progessive systemic sclerosis (PSS) with estriol treatment. Acta Derm Venereol 1984;64:168-171.
31. Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001;28:2257-2262.
32. Oriente P, Scarpa R, Biondi C, et al. Progressive systemic sclerosis and S-adenosylmethionine. Clin Rheumatol 1985;4:360-361.
33. Pierce HE Jr. Pineapple proteases in the treatment of scleroderma. A case report. J Natl Med Assoc 1964;56:272-273.
34. Jablonska S. Avocado/soybean unsaponifiables in the treatment of scleroderma: comment on the article by Maheu et al. Arthritis Rheum 1998;41:1705.
35. Cantwell AR Jr, Craggs E, Wilson JW, Swatek F. Acid-fast bacteria as a possible cause of scleroderma. Dermatologica 1968;136:141-150.
36. Mohrenschlager M, Jung C, Ring J, Abeck D. Effect of penicillin G on corium thickness in linear morphea of childhood: an analysis using ultrasound technique. Pediatr Dermatol 1999;16:314-316.
37. Svenson KL, Hallgren R, Johansson E, Lindh U. Reduced zinc in peripheral blood cells from patients with inflammatory connective tissue diseases. Inflammation 1985;9:189-199.
38. Keiser HR, Henkin RI, Bartter FC, Sjoerdsma A. Loss of taste during therapy with penicillamine. JAMA 1968;203:381-383.
39. Ambanelli U, Ferraccioli GF. D-Penicillamine and zinc. Arthritis Rheum 1978;21:396.
40. Fosmire GJ. Zinc toxicity. Am J Clin Nutr 1990;51:225-227.